Porton Biotech and Tianyu Life have reached a strategic cooperation to jointly promote the research and commercialization of NK cell therapy
According to Porton, on September 2nd, Suzhou Porton Biopharma Co., Ltd. and Zhejiang Tianyu Life Technology Co., Ltd. announced a strategic cooperation to jointly promote the research and industrialization of NK cell therapy technology. According to the agreement, Porton Biopharma will provide process development, GMP production, and registration application services for Tianyu Life's NK cell therapy project, assisting Tianyu Life in successfully obtaining clinical approval for its NK cell therapy drugs
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments